NCT06924190 - Pharmacokinetics and Bioequivalence Study of Budesonide Inhalation Aerosol in Humans | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

January 20, 2025

Study Completion Date

January 20, 2025

Conditions

Bioequivalence Study in Healthy Subjects

Interventions

DRUG

Budiair® 200ug/puff inhalation aerosol

The subjects randomly received one puff Budiair®(budesonide inhalation aerosol 200ug/puff )

DRUG

budesonide 200ug/puff inhalation aerosol

The subjects randomly received one puff budesonide inhalation aerosol(200ug/puff )

Trial Locations (2)

Wuxi People's Hospital, Wuxi

Lunan Better Pharmaceutical Co., Ltd., Linyi

All Listed Sponsors

collaborator

Wuxi People's Hospital

OTHER

lead

Lunan Better Pharmaceutical Co., LTD.

INDUSTRY